Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Linnaeus Bioscience is a bioscience research services company based on discoveries from the Pogliano Lab at UC San Diego. Founded in 2012, its core focus is accelerating antibacterial drug discovery, especially research related to antibiotic-resistant bacteria. Judging strictly from the information on its website, it is not a typical self-serve SaaS product that users can purchase and log into directly; instead, it mainly delivers laboratory services, platform capabilities, and custom projects.
Its core technology is Bacterial Cytological Profiling (BCP), which uses fluorescent probes, microscopy imaging, and quantitative cell biology methods to observe how compounds affect microbial cell morphology and physical characteristics, thereby helping determine mechanism of action (MOA). According to the website, BCP can determine MOA in about 2 hours and identify mechanism categories such as membrane permeability, peptidoglycan synthesis, lipid synthesis, translation, transcription, and DNA replication. It can also detect compounds at concentrations below the MIC, complex MOAs, and cytological changes under non-lethal conditions. The platform has also been extended to mycobacteria and fungal pathogens, and combines proprietary AI software, machine-learning pipelines, and more than ten years of phenotypic database resources.
The website does not disclose packages, subscription pricing, free trials, or standard SLAs. Instead, it emphasizes designing specific experiments based on each client’s discovery and development project. As a result, procurement is most likely project-based or handled through custom quotes. It is better suited to pharmaceutical companies, biotech companies, or research teams with clear research goals and samples, rather than software teams looking for an out-of-the-box tool.
Its strengths are clear technical positioning and practical relevance: BCP can be applied to samples such as natural product extracts, small molecules, and peptides, and can support hit screening, lead optimization, SAR analysis, and target engagement validation. Its team members and advisors also have strong backgrounds in anti-infective drug R&D. The limitations are also obvious: the website does not explain data security compliance, customer data handling, permission-based collaboration, cloud deployment, self-hosting, or API capabilities. The only third-party integration visible is an entry point via Scientist.com, making it difficult to assess its broader systematic integration capabilities.
It is better suited to teams working on antibacterial drug discovery, natural product screening, MIC testing, MOA determination, and antifungal or bacteriophage-related projects. Access from China cannot be determined from the website content alone. Network access, cross-border payments, contracts, sample shipping, and compliance approvals should be confirmed separately. If localized delivery is required, it may be worth comparing domestic CROs, microbial testing platforms, or AI drug discovery service providers in China.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on linnaeusbio.com official site.
linnaeusbio.com is an United States Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach linnaeusbio.com directly.